EPCAM and cancer: Compared with the anti-EpCAM monoclonal antibody (de Bono et al., 2004), CD3×EpCAM BsAb (Catumaxomab and MT110) exhibited a better efficacy against EpCAM-positive cancer in clinical trials (Heiss et al., 2010; Münz et al., 2010; Kebenko et al., 2018).